LH Laboratory Corporation of America Holdings

LabCorp to Webcast Its Annual Meeting of Shareholders

LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 10, 2018 at 9:00 a.m. Eastern Daylight Time via the Company website at www.labcorp.com. An archived replay of the audio webcast will be available for one year.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of more than $10 billion for 2017. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

This press release contains forward-looking statements including but not limited to statements with respect to estimated 2018 guidance and the related assumptions, the impact of various factors on operating and financial results, expected savings and synergies (including from the LaunchPad initiative and from acquisitions), and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, adverse results in material litigation matters, the impact of changes in tax laws and regulations, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, employee relations, and the effect of exchange rate fluctuations. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2017, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2017, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

EN
03/05/2018

Underlying

Reports on Laboratory Corporation of America Holdings

Laboratory Corp Of America Holdings: 2 directors

Two Directors at Laboratory Corp Of America Holdings sold/sold after exercising options 5,275 shares at 218.450USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the c...

Laboratory Corporation of America Holdings: Update to credit analysis

Our credit view of this issuer reflects its good customer and geographic diversification and its stable cash flow, against its pricing pressures in core testing business.

 PRESS RELEASE

Labcorp Announces 2022 Third Quarter Results

BURLINGTON, N.C.--(BUSINESS WIRE)-- Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the third quarter ended Sept. 30, 2022, and updated full-year guidance. "Labcorp made important strategic progress this quarter and is well positioned to deliver sustained value and growth,” said Adam Schechter, chairman and CEO of Labcorp. “We are focusing on science, innovation and technology to serve our customers' needs. Our Diagnostics Base Business performed well, and our Drug Development Base Business fundamentals remain strong, despite challenging year-over-year ...

Laboratory Corporation of America Holdings: Update to credit analysis ...

Our credit view of this issuer reflects its low financial leverage and stable cash flow, constrained by pricing pressures in the core lab business.

Moody's affirms Laboratory Corporation of America Holdings' Baa2 senio...

Moody's Investors Service, ("Moody's") affirmed Laboratory Corporation of America Holdings' ("Labcorp") Baa2 senior unsecured rating. The outlook is stable. The affirmation of the Baa2 rating follows Labcorp's announcement on July 28, 2022 that it plans to spin off its clinical development busines...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch